A Significant Milestone for Rare Blood Disorders HUTCHMED (China) Limited has recently announced a major regulatory achievement for its investigational drug, sovleplenib. The U.S. Food and Drug Administration (FDA) has officially granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia (ITP). Understanding Primary Immune Thrombocytopenia Primary immune thrombocytopenia is a rare…